SG Americas Securities
RAPP

SG Americas Securities’s Rapport Therapeutics RAPP Stock Holding History

SG Americas Securities’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$118K Sell
3,776
-5,897
-61% -$166K ﹤0.01% 2876
2025
Q4 		$293K Buy
9,673
+3,408
+54% +$94.3K ﹤0.01% 2763
2025
Q3 		$186K Buy
+6,265
New +$112K ﹤0.01% 2790
2024
Q4 		– Sell
-4,934
Closed -$101K – 3707
2024
Q3 		$101K Buy
+4,934
New +$106K ﹤0.01% 3077

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SG Americas Securities's RAPP Position: Q1 2026 in Review

SG Americas Securities reduced its Rapport Therapeutics (RAPP) stake by 61% in Q1 2026, selling an estimated $166K and leaving 3,776 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #2876.

SG Americas Securities first reported a position in RAPP in Q3 2024 and has held it in 4 quarters since. The position peaked at $293K in Q4 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • SG Americas Securities held 3,776 shares of Rapport Therapeutics worth $118K as of Q1 2026.
  • SG Americas Securities sold 5,897 Rapport Therapeutics shares in Q1 2026, an estimated $166K.
  • Rapport Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2876 holding.
  • SG Americas Securities first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • SG Americas Securities's Rapport Therapeutics position peaked at $293K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.